A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Clinical trial NCT04031885 · TERMINATED
Trial details
- NCT number
- NCT04031885
- Sponsor
- Eli Lilly and Company
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-14
- Primary completion
- 2020-08-11
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.